Stock Monitor: Fonar Post Earnings Reporting
LONDON, UK / ACCESSWIRE / February 21, 2018 / Active-Investors.com has just released a free earnings report on Boston Scientific Corp. (NYSE: BSX). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BSX. The Company reported its fourth quarter fiscal 2017 and full fiscal year 2017 operating and financial results on February 01, 2018. The medical device maker topped revenue estimates, while earnings were in-line with market expectations. The Company provided guidance for the upcoming quarter and fiscal year. Register today and get access to over 1000 Free Research Reports by joining our site below:
Active-Investors.com is currently working on the research report for Fonar Corporation (NASDAQ: FONR), which also belongs to the Healthcare sector as the Company Boston Scientific. Do not miss out and become a member today for free to access this upcoming report at:
Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Boston Scientific most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:
Earnings Highlights and Summary
Boston Scientific generated sales of $2.41 billion during the fourth quarter ended December 31, 2017, representing a growth of 9.9% compared to $2.19 billion for Q4 2016. The strong top-line exceeded the Company's guidance range of $2.345 billion to $2.375 billion, due to outperformance across the majority of its businesses and regions. Boston Scientific's revenue numbers topped analysts' estimates of $2.38 billion.
During Q4 2017, Boston Scientific's adjusted gross margin was 72.6%, and was flat compared to the prior year's same period, but more importantly offset a negative 200-basis point y-o-y impact from foreign exchange, benefitting from operational improvements and manufacturing cost reductions, as well as a favorable product mix. In Q4 2017, the Company's adjusted operating margin of 25.6% increased 190 basis points y-o-y.
Boston Scientific reported a GAAP loss of $615 million, or $0.45 loss per share, primarily related to its estimates of a one-time net income tax charge resulting from the enactment of the Tax Cuts and Jobs Act 2017 (TCJA), compared to GAAP earnings of $124 million, or $0.09 per share, in Q4 2016. The Company achieved adjusted earnings per share (EPS) of $0.34 for the reported quarter versus $0.30 in the year ago comparable period, and which were in-line with Wall Street's estimates of $0.34.
For the year ended December 31, 2017, Boston Scientific recorded sales of $9.05 billion, representing a 7.9% revenue growth on a reported basis, from $8.39 billion in FY16.
For FY17, Boston Scientific reported GAAP earnings of $104 million, or $0.08 per share, compared to $347 million, or $0.25 per share, in Q4 2016; and delivered full year adjusted EPS of $1.26 compared to $1.11 in FY16.
During Q4 2017, Boston Scientific's Cardiovascular segment recorded sales of $3.50 billion, up 6.3% compared to $3.29 billion in Q4 2016.
In the reported quarter, the Company's Rhythm Management segment's sales totaled $2.17 billion versus $2.09 billion in the year earlier corresponding quarter, reflecting a growth of 3.9% on a y-o-y basis.
For Q4 2017, Boston Scientific's Medsurg segment's net sales advanced 12.5% to $3.38 billion versus $3.00 billion in Q4 2016.
Boston Scientific's adjusted free cash flow was $1.73 billion in FY17, representing a y-o-y growth of 7%, but fell slightly short of its $1.75 billion cash flow guidance. Boston Scientific's capital expenditure totaled $319 million for FY17, in-line with its $320 million target.
For the full year 2018, Boston Scientific is forecasting revenues to be in a range of $9.65 billion to $9.80 billion, representing a growth range of approximately 7% to 8% on a y-o-y basis. The Company is estimating income per share on a GAAP basis in a range of $0.93 to $0.98, and adjusted EPS, excluding amortization expenses, acquisition- and restructuring-related net credits (charges), in the band of $1.35 to $1.39.
For Q1 2018, Boston Scientific is projecting sales to be in a range of $2.32 billion to $2.35 billion, reflecting a growth range of approximately 7% to 9% on a reported basis. The Company is expecting GAAP EPS in the band of $0.19 to $0.22, and adjusted EPS, excluding amortization expenses, acquisition- and restructuring-related net credits (charges) in the band of $0.30 to $0.32.
Stock Performance Snapshot
February 20, 2018 - At Tuesday's closing bell, Boston Scientific's stock declined 1.36%, ending the trading session at $26.83.
Volume traded for the day: 7.04 million shares.
Stock performance in the past twelve-month period – up 5.67%; and year-to-date – up 8.23%
After yesterday's close, Boston Scientific's market cap was at $36.69 billion.
Price to Earnings (P/E) ratio was at 38.55.
The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry.
Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
A-I has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 73 29 92 6381
Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.